Different serological assays measuring anti–SARS-CoV-2 antibodies and their neutralizing activity in samples from individuals with severe and mild COVID-19 are compared. Elucidating seroprevalence in COVID-19 Individuals infected with SARS-CoV-2 mount an antibody response that may vary depending on the severity of the disease. Grzelak et al. assessed the amounts of anti–SARS-CoV-2 antibodies in serum samples from 491 healthy individuals before the pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. The authors developed and compared the performance of four different serological assays measuring antibody amounts and their neutralizing activity. The assays enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in asymptomatic, mildly symptomatic, and severe cases of COVID-19. It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we performed a pilot study of four serological assays to assess the amounts of anti–SARS-CoV-2 antibodies in serum samples obtained from 491 healthy individuals before the SARS-CoV-2 pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. We used two ELISA assays that recognized the full-length nucleoprotein (N) or trimeric spike (S) protein ectodomain of SARS-CoV-2. In addition, we developed the S-Flow assay that recognized the S protein expressed at the cell surface using flow cytometry, and the luciferase immunoprecipitation system (LIPS) assay that recognized diverse SARS-CoV-2 antigens including the S1 domain and the carboxyl-terminal domain of N by immunoprecipitation. We obtained similar results with the four serological assays. Differences in sensitivity were attributed to the technique and the antigen used. High anti–SARS-CoV-2 antibody titers were associated with neutralization activity, which was assessed using infectious SARS-CoV-2 or lentiviral-S pseudotype virus. In hospitalized patients with COVID-19, seroconversion and virus neutralization occurred between 5 and 14 days after symptom onset, confirming previous studies. Seropositivity was detected in 32% of mildly symptomatic individuals within 15 days of symptom onset and in 3% of healthy blood donors. The four antibody assays that we used enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in different subpopulations within one region.
【초록키워드】 COVID-19, SARS-CoV-2, pandemic, Hospitalized, antibody, SARS-COV-2 infection, severity, Antibody Response, flow cytometry, Antigen, Prevalence, Protein, sensitivity, Neutralizing activity, Seroconversion, SARS-CoV-2 seroprevalence, Serological assay, Asymptomatic, serological assays, symptomatic, Antibody titer, Virus neutralization, Seropositivity, Mild, SARS-CoV-2 antigen, antibody assay, mild symptoms, ELISA assay, antibody profiling, symptom onset, Luciferase immunoprecipitation system, LIPS, Previous studies, pilot study, individual, domain, profiles, Severe case, neutralization activity, symptomatic case, ectodomain, immunoprecipitation, healthy blood donors, trimeric spike, pseudotype virus, subpopulation, full-length, serum sample, S1 domain, Cell, difference, performed, evaluate, occurred, addition, the disease, hospitalized patient, expressed, the S protein, healthy individual, infected with SARS-CoV-2, symptomatic individual, the SARS-CoV-2, with COVID-19, 【제목키워드】 antibody, Population, Serological assay, human serum,